Tilray | TRLY - Operating Profit

Stock Price
1.53
Daily Change
-0.11 -6.71%
Monthly
20.47%
Yearly
-34.05%
Q3 Forecast
1.63

Tilray reported $-42218000 in Operating Profit for its fiscal quarter ending in November of 2024.



Financials
Stock Price USD
Assets USD 4.19B
Cash and Equivalent USD 189.7M
Cost of Sales USD 149.73M
Current Assets USD 707.34M
Current Liabilities USD 278.52M
Debt USD 351.72M
EBIT USD -42.22M
EBITDA USD -101K
Employees USD 2.65K
EPS Earnings Per Share USD -1.78
Equity Capital and Reserves USD 3.47B
Gross Profit on Sales USD 61.22M
Interest Expense on Debt USD 7.77M
Interest Income USD 12.83M
Loan Capital USD 316.63M
Market Capitalization USD 1.18B
Net Income USD -85.34M
Operating Expenses USD 253.17M
Operating Profit USD -42.22M
Ordinary Share Capital USD 93K
Pre-Tax Profit USD -83.24M
Sales Revenues USD 308.01M
Selling and Administration Expenses USD 72.38M
Stock USD 266.01M
Trade Creditors USD 99.08M
Trade Debtors USD 112.74M

Operating Profit Change Date
Acasti Pharma USD -3090000 614K Jun/2025
Alaunos Therapeutics USD -755000 395K Dec/2024
Aurora Cannabis CAD -20220000 56.44M Jun/2025
Avita Medical AUD -9957000 5.64M Dec/2024
Canopy Growth CAD -22080000 1.74M Jun/2025
Cronos Group USD -4384000 312K Jun/2025
Dianthus Therapeutics USD -34927000 3.01M Jun/2025
Divis Laboratories Ltd 6.17B 1.62B Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
IQVIA Holdings USD 556M 64M Jun/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Moderna USD -907000000 143M Jun/2025
Organigram Holdings CAD -2100000 9.2M Jun/2025
Organon & Co USD 326M 225M Jun/2025
Revvity USD 90.76M 18.53M Jun/2025
Tectonic Therapeutic USD -22330000 8.34M Jun/2025
Tilray USD -42218000 5.65M Nov/2024
Viatris USD 185.4M 3.21B Jun/2025
Xeris Pharmaceuticals USD 4.48M 2.8M Jun/2025